View on Pubmed.gov 30126953 | View on doi.org 10.1128/AAC.010...
Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects.
- University of Illinois at Chicago, Chicago, Illinois, USA kar@uic.edu.
- University of Illinois at Chicago, Chicago, Illinois, USA.
- Pulmonary Associates, PA, Phoenix, Arizona, USA.
- Entasis Therapeutics, Inc., Waltham, Massachusetts, USA.
Abstract
ETX2514 is a novel β-lactamase inhibitor that broadly inhibits Ambler class A, C, and D β-lactamases. ETX2514 combined with sulbactam (SUL) restores sulbactam activity against ETX2514-sulbactam (ETX2514SUL) is under development for the treatment of infections. The objective of this study was to determine and compare plasma, epithelial lining fluid (ELF), and alveolar macrophage (AM) concentrations following intravenous (i.v.) ETX2514 and sulbactam. Plasma, ELF, and AM concentrations of ETX2514 and sulbactam were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in 30 healthy adult subjects following repeated dosing (ETX2514 [1 g] and sulbactam [1 g] every 6 h [q6h], as a 3-h i.v. infusion, for a total of 3 doses). A bronchoalveolar lavage (BAL) was performed once in each subject at either 1, 2.5, 3.25, 4, or 6 h after the start of the last infusion. Penetration ratios were calculated from area under the concentration-time curve from 0 to 6 h (AUC) values for total plasma and ELF using mean and median concentrations at the BAL fluid sampling times. Respective ELF AUC values, based on mean and median concentrations, were 40.1 and 39.4 mg · h/liter for ETX2514 and 34.7 and 34.5 mg · h/liter for sulbactam. Respective penetration ratios of ELF to total/unbound plasma concentrations, based on mean and median AUC values, of ETX2514 were 0.37/0.41 and 0.36/0.40, whereas these same ratio values were 0.50/0.81 and 0.50/0.80 for sulbactam. ETX2514 and sulbactam concentrations in AM were measurable and fairly constant throughout the dosing interval (median values of 1.31 and 1.01 mg/liter, respectively). These data support further study of ETX2514SUL for the treatment of pneumonia caused by multidrug-resistant (This study has been registered at ClinicalTrials.gov under identifier NCT03303924.).
References
Clin Microbiol Infect. 2014 May;20(5):416-23
Antimicrob Agents Chemother. 2003 Aug;47(8):2450-7
J Hosp Med. 2016 Jan;11(1):21-6
J Microbiol. 2017 Nov;55(11):837-849
Cited by 58 citations (total)
Journal Article Review
Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors.
Electronic publication date July 3, 2021
Giacomo Luci [...] Antonello Di Paolo et al.
The growing emergence of drug-resistant bacterial strains is an issue to treat severe infections, and many efforts have identified new...
Journal Article
Occurrence of Multidrug-Resistant Strains of spp.: An Emerging Threat for Nosocomial-Borne Infection in Najran Region, KSA.
Electronic publication date February 25, 2023
Abdullah I Aedh [...] Abdulkarim Hasan et al.
Multidrug-resistant strains are frequent causes of nosocomial infections. The majority of nosocomial infections, particularly in critical care units (ICU), have...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
- •
Substances
- •
- •
- •
Copyright
Copyright © 2018 American Society for Microbiology.